ROLE OF OCT-ANGIOGRAPHY IN STUDYING OF PATHOGENESIS, DIAGNOSTICS AND MONITORING THE MACULAR TELANGIECTASIES IN CHILDREN


Cite item

Full Text

Abstract

The purpose. to assess the potential of OCT-angiography in studying pathogenesis, diagnosing and monitoring macular telangiectasias of various genesis in children and adolescents. Material and methods. We examined and treated 4 children (5 eyes) aged from 12 to 17 years with idiopathic macular telangiectasias (2), developed against the background of Coat’s disease (1) and diabetic retinopathy (1). The examination included standard ophthalmologic inspection, as well as optical coherence tomography and OCT-angiography (RS-3000 Advance AngioSca, Nidek, Japan). Two children underwent transpupillary laser coagulation of telangiectasias (2 and 3 sessions), two received an intravitreal injection of an inhibitor of angiogenesis. Results. Ophthalmoscopically in all children microaneurysms were localized in the macular and paramacular zones and were accompanied by the development of retinal edema. According to OCT-angiography, all children had pathological structural changes (microaneurysms, vascular artery abnormalities, changes in the density of the vascular pattern) of superficial and to a greater extent deep retinal capillary plexuses. As a result of the treatment, 3 children (4 eyes) had clinically noted decrease in the number of microaneurysms. According to the data of optical coherence tomography, there was positive dynamics in decrease of the height of the retinal edema from 49 to 320 μm, аccording to OCT angiography, showed a decrease in the number of microaneurysms in the superficial and especially in the deep plexus, and in a child with diabetic retinopathy there was also a slight increase in the vascular density of the deep capillary plexus. Сonclusion. According to OCT-angiography, development of macular telangiectasias in children is accompanied by preferential changes in the deep capillary plexus, which indicates the pathogenetic significance of microcirculatory disturbances at this level. The method also reveals its value in monitoring the disease.

About the authors

L. A Katargina

The Helmholtz Moscow Research Institute of Eye Diseases of the Ministry of Health

Moscow, 105062, Russian Federation

E. V Denisova

The Helmholtz Moscow Research Institute of Eye Diseases of the Ministry of Health

Moscow, 105062, Russian Federation

Natal’ja A. Osipova

The Helmholtz Moscow Research Institute of Eye Diseases of the Ministry of Health

Email: natashamma@mail.ru
ophthalmologist of ophthalmology department (pediatric surgery) of The Helmholtz Moscow Research Institute of Eye Diseases of the Ministry of Health of the Russian Federation Moscow, 105062, Russian Federation

L. V Kogoleva

The Helmholtz Moscow Research Institute of Eye Diseases of the Ministry of Health

Moscow, 105062, Russian Federation

A. O Tarasenkov

The Helmholtz Moscow Research Institute of Eye Diseases of the Ministry of Health

Moscow, 105062, Russian Federation

M. V Belova

The Helmholtz Moscow Research Institute of Eye Diseases of the Ministry of Health

Moscow, 105062, Russian Federation

O. V Novikova

The Helmholtz Moscow Research Institute of Eye Diseases of the Ministry of Health

Moscow, 105062, Russian Federation

References

  1. Nowilaty S.R., Al-Shamsi H.N., Al-Khars W. Idiopathic juxtafoveolar retinal telangiectasis: a current review. Middle East Afr. J. Ophthalmol. 2010; 17: 224-41.
  2. Baz Ö., Yılmaz I., Alagöz C., Demircan A., Perente I., Özkaya A., Taşkapılı M. Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia. Turk. J. Ophthalmol. 2017; 47: 144-8. doi: 10.4274/tjo.04874.
  3. Özkaya A., Yazıcı A.T., Demirok A. Jukstafoveal Telenjiektaziler. Ret.-Vit. 2012; 20: 13-21.
  4. Gass J.D., Blodi B.A. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993; 100(10): 1536-46.
  5. Yannuzzi L.A., Bardal A.M., Freund K.B., Chen K.J., Eandi C.M., Blodi B. Idiopathic macular telangiectasia. Arch. Ophthalmol. 2006; 124: 450-60.
  6. Wu L., Evans T., Arevalo J.F. Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2). Surv. Ophthalmol. 2013; 58(6): 536-59.
  7. Nowilaty S.R., Al-Shamsi H.N., Al-Khars W. Idiopathic juxtafoveolar retinal telangiectasis: a current review. Middle East Afr. J. Ophthalmol. 2010; 17: 224-41.
  8. Park D.W., Schatz H., McDonald H.R., Johnson R.N. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology. 1997; 104: 1838-46.
  9. Alldredge C.D., Garretson B.R. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina. 2003; 23:113-6.
  10. Raza S., Toklu Y., Anayol M.A., Şimşek Ş., Özkan B., Altıntaş A.K. Comparison between efficacy of triamcinolone acetonide and bevacizumab in a case with type 2A idiopathic parafoveal telangiectasia. Turk. J. Ophthalmol. 2011; 41: 6-9.
  11. Roller A.B., Folk J.C., Patel N.M., Boldt H.C., Russell S.R., Abramoff M.D., Mahajan V.B. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina. 2011; 31: 1848-55.
  12. Kashani A.H., Chen C.L., Gahm J.K., Zheng F., Richter G.M., Rosenfeld P.J., Shi Y., Wang R.K. Optical coherence tomography angiography: A comprehensive review of current methods and clinical applications. Prog. Retin. Eye Res. 2017; 60: 66-100. doi: 10.1016/j.preteyeres.2017.07.002.

Copyright (c) 2018 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies